Search

Author/Creator Mathieu, Luckson

1. FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. (14th December 2017)

Authors:
Odogwu, Lauretta; Mathieu, Luckson; Goldberg, Kirsten B.; Blumenthal, Gideon M.; Larkins, Erin; Fiero, Mallorie H.; Rodriguez, Lisa; Bijwaard, Karen; Lee, Eunice Y.; Philip, Reena; Fan, Ingrid; Donoghue, Martha; Keegan, Patricia; McKee, Amy; Pazdur, Richard
Journal:
Oncologist
Issue:
Volume 23:Number 3(2018)
Page Start:
353
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations. (7th February 2018)

Authors:
Odogwu, Lauretta; Mathieu, Luckson; Blumenthal, Gideon; Larkins, Erin; Goldberg, Kirsten B.; Griffin, Norma; Bijwaard, Karen; Lee, Eunice Y.; Philip, Reena; Jiang, Xiaoping; Rodriguez, Lisa; McKee, Amy E.; Keegan, Patricia; Pazdur, Richard
Journal:
Oncologist
Issue:
Volume 23:Number 6(2018)
Page Start:
740
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. (25th March 2021)

Authors:
Mathieu, Luckson; Shah, Sujay; Pai‐Scherf, Lee; Larkins, Erin; Vallejo, Jonathon; Li, Xiaoxue; Rodriguez, Lisa; Mishra‐Kalyani, Pallavi; Goldberg, Kirsten B.; Kluetz, Paul G.; Theoret, Marc R.; Beaver, Julia A.; Pazdur, Richard; Singh, Harpreet
Journal:
Oncologist
Issue:
Volume 26:Number 5(2021)
Page Start:
433
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search